Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 7/2017

01.07.2017 | Evolving Therapies (R Bukowski, Section Editor)

Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)

verfasst von: Kit Man Wong, Kathryn J. Horton, Andrew L. Coveler, Sunil R. Hingorani, William P. Harris

Erschienen in: Current Oncology Reports | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

The tumor stroma is increasingly recognized as a key player in tumorigenesis through its effects on cell signaling, immune responses, and access of therapeutic agents. A major component of the extracellular matrix is hyaluronic acid (HA), which raises the interstitial gel fluid pressure within tumors and reduces drug delivery to malignant cells, and has been most extensively studied in pancreatic ductal adenocarcinoma (PDA). Pegylated recombinant human hyaluronidase (PEGPH20) is a novel agent that degrades HA and normalizes IFP to enhance the delivery of cytotoxic agents. It has demonstrated promising preclinical results and early clinical evidence of efficacy in the first-line treatment of metastatic PDA with acceptable tolerability. Moreover, intratumoral HA content appears to be a predictive biomarker of response. Phase 2 and 3 trials of PEGPH20 plus chemotherapy are ongoing in metastatic PDA, and it is also being evaluated in other malignancies and in combination with radiation and immunotherapy.
Literatur
1.
2.
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482–92.CrossRefPubMed
3.
4.
• Thompson CB, Shepard HM, O’Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010;9:3052–64. This was the first preclincal evaluation of PEGPH20. It demonstrated that PEGPH20 effectively decreased tumor HA, reduced IFP, increased tumor vasculature, and inhibited tumor growth in a xenograft prostate-cancer model.
5.
• Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–29. This study demonstrated the role of HA in the resistance of PDAs and provided convincing preclinical evidence for PEGPH20 in an autochthonous murine PDA model. Importantly, a randomized placebo-controlled trial of gemcitabine in combination with PEGPH20 vs. placebo in the PDA murine model showed superior overall survival with the addition of PEGPH20. CrossRefPubMedPubMedCentral
6.
Jiang P, Li X, Thompson CB, et al. Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res. 2012;32:1203–12.PubMed
7.
Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21:3561–8.CrossRefPubMedPubMedCentral
8.
•• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22:2848–54. This Phase 1b study established the safety, tolerability and maximal tolerated dose of PEGPH20 with gemcitabine in PDA patients. This study demonstrated a sigificant objective response rate with PEGPH20. CrossRefPubMed
9.
Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–39.CrossRefPubMed
10.
Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62:112–20.CrossRefPubMed
11.
Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res. 2011;317:383–91.CrossRefPubMed
12.
Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel). 2012;4:873–903.CrossRef
13.
Setala LP, Tammi MI, Tammi RH, et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer. 1999;79:1133–8.CrossRefPubMedPubMedCentral
14.
Whatcott CJ, Jiang P, Watanabe A. Hyaluronan deposition correlates with poor survival in pancreatic cancer. Cancer Res. 2011;71:abstr LB-307.CrossRef
15.
Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186–97.CrossRefPubMed
16.
Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518–27.CrossRefPubMed
17.
Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 1993;73:1–78.PubMed
18.
Sherwood L. Human physiology from cells to systems. Third ed. Florence: Wadsworth Publishing Company; 1997.
19.
De Smedt SC, Lauwers A, Demeester J, Engelborghs Y, De Mey G, Du M. Structural information on hyaluronic acid solutions as studied by probe diffusion experiments. Macromolecules. 1994;27:141–6.CrossRef
20.
Bian L, Guvendiren M, Mauck RL, Burdick JA. Hydrogels that mimic developmentally relevant matrix and N-cadherin interactions enhance MSC chondrogenesis. Proc Natl Acad Sci U S A. 2013;110:10117–22.CrossRefPubMedPubMedCentral
21.
Blundell CD, Seyfried NT, Day AJ. Chapter 8: structural and functional diversity of hyaluronan-binding proteins. In: Garg HG, Hales CA, editors. Chemistry and biology of hyaluronan. Elsevier: Oxford; 2004.
22.
Garg HG, Hales CA. Chapter 6: the role of hyaluronan receptor RHAMM in wound repair and tumorigenesis. Garg HG, Hales CA, eds. Elsevier: In; 2004.
23.
Ingber DE. Mechanical control of tissue morphogenesis during embryological development. Int J Dev Biol. 2006;50:255–66.CrossRefPubMed
24.
Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–7.CrossRefPubMed
25.
Hofmann M, Rudy W, Gunthert U, et al. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993;53:1516–21.PubMed
26.
Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem. 2003;278:29420–34.CrossRefPubMed
27.
Cheng XB, Sato N, Kohi S, Koga A, Hirata K. Receptor for hyaluronic acid-mediated motility is associated with poor survival in pancreatic ductal adenocarcinoma. J Cancer. 2015;6:1093–8.CrossRefPubMedPubMedCentral
28.
Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–83.CrossRefPubMed
29.
Borad MJ, Ramanathan RK, Bessudo A. Targeting hyaluronan (HA) in tumor stroma: a phase I study to evaluate the safety, pharmacokinetics (PK), andpharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. J Clin Oncol. 2012;30(suppl):abstr 2579.
30.
Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33:2028–34.CrossRefPubMed
31.
Habib M, Saif MW. Thromboembolism and anticoagulation in pancreatic cancer. Jop. 2013;14:135–7.PubMed
32.
• Hingorani S, Harris W, Seery T, et al. Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer. 2016 Gastrointestinal cancers symposium. This abstract presented the interim analysis of the Phase 2 trial of PEGPH20 with gemcitabine and nab-paclitaxel in the first-line treatment of metastatic PDA. The preliminary results showed improved signfiicantly increased progression-free survival and objective response rate in the experimental arm in patients with HA-high tumors.
33.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefPubMedPubMedCentral
34.
Bullock AJ, Hingorani SR, Wu XW. Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay. J Clin Oncol. 2016;34(suppl):abstr 4104.
35.
Hingorani SR, Harris WP, Beck JT. Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA). J Clin Oncol. 2015;33(suppl 3):abstr 300.CrossRef
36.
Maneval DC, Ramanathan RK, Infante JR. Abstract 2672: phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors. Cancer Res. 2012;72(8 suppl):abstr 2672.CrossRef
37.
Singha NC, Nekoroski T, Zhao C, et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther. 2015;14:523–32.CrossRefPubMed
38.
Bollyky PL, Wu RP, Falk BA, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A. 2011;108:7938–43.CrossRefPubMedPubMedCentral
39.
Padrnos LJ, Marella M, Kosiorek H. Assessment of hyaluronic acid in tumor microenvironment (TME) of intrahepatic cholangiocarcinoma (CCA). J Clin Oncol. 2016;34(suppl 4S):abstr 248.CrossRef
40.
Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–54.CrossRefPubMed
41.
DuFort CC, DelGiorno KE, Hingorani SR. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology. 2016;150:1545–57. e2 CrossRefPubMedPubMedCentral
42.
Matrosova VY, Orlovskaya IA, Serobyan N, Khaldoyanidi SK. Hyaluronic acid facilitates the recovery of hematopoiesis following 5-fluorouracil administration. Stem Cells. 2004;22:544–55.CrossRefPubMed
43.
Khaldoyanidi S, Moll J, Karakhanova S, Herrlich P, Ponta H. Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Blood. 1999;94:940–9.PubMed
44.
Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013;18:1321–9.CrossRefPubMedPubMedCentral
45.
Verheye S, Markou CP, Salame MY, et al. Reduced thrombus formation by hyaluronic acid coating of endovascular devices. Arterioscler Thromb Vasc Biol. 2000;20:1168–72.CrossRefPubMed
Metadaten
Titel
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
verfasst von
Kit Man Wong
Kathryn J. Horton
Andrew L. Coveler
Sunil R. Hingorani
William P. Harris
Publikationsdatum
01.07.2017
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 7/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0608-3

Weitere Artikel der Ausgabe 7/2017

Current Oncology Reports 7/2017 Zur Ausgabe

Cardio-oncology (EH Yang, Section Editor)

Cardiac Amyloidosis: Diagnosis and Treatment Strategies

Lung Cancer (JM Johnson, Section Editor)

Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope

Gynecologic Cancers (NS Reed, Section Editor)

Pediatric Gynecologic Cancers

Gastrointestinal Cancers (J Meyer, Section Editor)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma

Melanoma (RJ Sullivan, Section Editor)

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies

Breast Cancer (B Overmoyer, Section Editor)

Role of Aspirin in Breast Cancer Survival

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise